Pharma BD Deal Intelligence
Novartis paid $180M upfront in a $2.89B licensing/option deal for expanded access to PeptiDream's macrocyclic peptide discovery platform, spanning undisclosed indications plus PET imaging diagnostics. A platform bet, not an asset buy—value hinges on how many programs Novartis actually advances from an unproven discovery engine.
Novartis and PeptiDream ink potential $2.7B deal to expand radioligand discovery partnership using proprietary macrocyclic peptide platform technology.
PMLiVE reports Novartis and PeptiDream expanded their peptide discovery collaboration in a deal worth over $2.8B total ($180M upfront plus up to $2.71B in…
Novartis paid $180M upfront to expand its collaboration with PeptiDream for macrocyclic peptide platform access.
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Novartis expanded its collaboration with PeptiDream, paying $180M upfront for access to its macrocyclic peptide discovery platform across multiple undisclosed indications.
Novartis's PeptiDream deal adds PDPS-derived macrocyclic peptide-radionuclide conjugates to a radioligand pipeline Novartis already leads. Peptide-based radioligand therapies (direct MOA, Novartis franchise): Novartis's Pluvicto (177Lu-PSMA-617, mCRPC, approximately $1.4B 2024 sales) and Lutathera (177Lu-DOTATATE, GEP-NETs, approximately $720M 2024) anchor the approved peptide-radioligand category. Actinium-225 and alpha-emitter peptide conjugates (competing class): BMS/RayzeBio's RYZ101 (225Ac-DOTATATE, Phase 3 ACTION-1 NETs, $4.1B 2023 acquisition), AstraZeneca/Fusion's FPI-2059 (NTSR1) and FPI-2068 (EGFR/cMET, $2B 2024 acquisition), Perspective Therapeutics' VMT-alpha-NET (212Pb), and Lantheus/POINT's PNT2002 (177Lu-PSMA I&T, Phase 3 SPLASH). Antibody-radionuclide conjugates (alternative architecture): Bayer's thorium-227 TTCs (PSMA-TTC, MSLN-TTC Phase 1), Telix's Pixclara and Illuccix/Zircaix (imaging radioligands). Small-molecule radioligand: Novartis/3B Pharmaceuticals acquisition (2023) for FAP-targeted radioligands. Discovery-stage peptide platforms: Bicycle Therapeutics' Bicyclic Toxin Conjugates/Bicyclic Radionuclide Conjugates (BT8009, BT7480 pipeline), Ariceum Therapeutics' satoreotide, and Aktis Oncology's Aktide peptide-based alpha conjugates. For a commercial lead, PeptiDream's macrocyclic peptide library extends Novartis's radioligand platform but faces rising platform-enabled competition from BMS (RayzeBio), AstraZeneca (Fusion), and Bayer across PSMA, NTSR1, SSTR2, FAP, and undisclosed oncology targets.
Accelerated-phase CML BCR-ABL+ is a small patient population. Approved TKIs for CML-AP: imatinib (Gleevec, Novartis; generic), dasatinib (Sprycel, BMS), nilotinib (Tasigna, Novartis), bosutinib (Bosulif, Pfizer), ponatinib (Iclusig, Takeda; T315I-resistant), asciminib (Scemblix, Novartis; STAMP allosteric inhibitor, approved 2021 for CP-CML 3L+). Novartis/PeptiDream macrocyclic peptide-drug conjugate platform's AP-CML positioning is speculative — no specific program disclosed for this indication. Competitive context here is the Novartis TKI franchise (Gleevec, Tasigna, Scemblix) rather than a new platform entrant.
Novartis paid $180M upfront for peptide-drug conjugate discovery using PDPS platform.
Novartis paid $180M upfront for macrocyclic peptide discovery platform access for radioligand therapies.
Discovery-stage collaboration expanding 14-year relationship. Platform validation via multiple prior programs.
Long-standing relationship (since 2010). Platform generating candidates for radioligand and PDC applications.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / PeptiDream Inc. (this deal) | 2024 | $2.9B | 71 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2024 deals · Novartis AG deals · Oncology deals